In Rare Moves, Parmodia and Istodax to Skip Price Listing for 2nd Time

Kowa is taking a pass on the reimbursement listing of its hyperlipidemia hopeful Parmodia (pemafibrate) for the second consecutive time, as is Celgene for its lymphoma med Istodax (romidepsin), with the extremely rare moves signaling that drug makers’ price negotiations...read more